Effect of tirofiban on platelet activity in patients with progressive cerebral infarction and its application value
Objective To observe the effect of tirofiban on platelet activity in patients with progressive cerebral infarction(PCI)and its clinical application effect.Methods This was a randomized controlled trial.A total of 106 PCI patients admitted to Affiliated Hospital of Traditional Chinese Medicine,Nanyang Medical College from January 2021 to March 2023 were selected as the study objects,and were divided into a routine group and an experimental group by the random number table method,with 53 cases in each group.In the routine group,30 males and 23 females,aged(60.11±5.27)years,were treated with conventional medication;in the experimental group,31 males and 22 females,aged(61.25±5.33)years,were treated with tirofiban on the basis.The improvement of platelet function,inflammatory response,and neurological function before and after treatment were compared between the two groups,and the drug safety was evaluated.t test and x2 test were used.Results Before treatment,there were no statistically significant differences in the platelet activity,platelet function,inflammatory indexes,and neurological function between the two groups(all P＞0.05).After treatment,the levels of β-thromboglobulin(β-TG),granular membrane protein CD62P,CD63,platelet aggregation rate(PAgT),platelet adhesion rate(PAdT),interleukin-6(IL-6),IL-8,and C-reactive protein(CRP)in the experimental group were alllower than those in the routine group[(15.44±5.16)μg/L vs.(18.25±5.27)μg/L,(55.25±10.47)％vs.(61.45±10.46)％,(10.33±3.41)％vs.(12.28±3.16)％,(35.22±10.17)％vs.(42.11±10.48)％,(28.33±5.14)％vs.(31.45± 5.16)％,(60.44±10.28)ng/L vs.(67.62±10.35)ng/L,(10.15±3.22)ng/L vs.(12.37±3.19)ng/L,(7.66± 2.11)mg/L vs.(8.82±2.14)mg/L],with statistically significant differences(t=2.774,3.050,3.054,3.435,3.119,3.583,3.566,and 2.810,all P＜0.05).After 3,7,and 14 days of treatment,the National Institutes of Health Stroke Scale(NIHSS)scores of the experimental group were lower than those of the routine group[(30.25±5.14)points vs.(33.47±5.26)points,(24.33±5.18)points vs.(27.85±5.61)points,(20.12±5.41)points vs.(23.36±5.41)points],with statistically significant differences(t=3.188,3.356,and 3.083,all P＜0.05).After treatment,there was no statistically significant difference in the incidence of drug-related adverse reactions between the two groups(P＞0.05).Conclusions Tirofiban can effectively inhibit the platelet activity in patients with PCI,which is of positive significance in improving the platelet function,reducing the inflammatory reaction,and improving the neurological function.Combined use of this drug does not significantly increase the risk of drug-related adverse reactions,with high safety.
万方数据
维普
